<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Spontaneous intramedullary <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was measured in bone marrow (BM) biopsies of 175 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) using in situ end-labeling (ISEL) of fragmented DNA </plain></SENT>
<SENT sid="1" pm="."><plain>Two groups of high (n=71) versus low (n =43) levels of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> were identified while 61 patients were ISEL-negative </plain></SENT>
<SENT sid="2" pm="."><plain>Semiquantitative assessment of 3 cytokines, the number of macrophages and in vivo labeling indices (LI) were also determined from consecutive sections of the biopsy </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with high <z:mpath ids='MPATH_3'>apoptosis</z:mpath> levels tended to have a high LI (p=0.013), more macrophages in their BM biopsies (p=0.006) and higher <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (TNF-alpha) levels (not significant) compared to patients with no <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, low risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients had significantly lower rates of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (p = 0.047) and lower levels of TNF-alpha (p = 0.055) compared to high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="5" pm="."><plain>We conclude that the genesis of cytopenias in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is of multifactorial origin and that cytokine-associated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> clearly identifies a distinct biological subgroup of patients who may benefit selectively by use of anti-cytokine therapies </plain></SENT>
</text></document>